HERZLIYA PITUACH, Israel--(BUSINESS WIRE)--CorAssist, a developer of novel therapeutic devices for Diastolic Heart Failure (DHF), announced today its flagship product, the ImCardia™, significantly improved DHF parameters in a first-of-its-kind preclinical study and has shown preliminary safety in two humans after three months follow up.
